Patents Assigned to Hoffmann-La Roche
  • ANTIBODIES AGAINST HUMAN CSF-1R FOR USE IN INDUCING LYMPHOCYTOSIS IN LYMPHOMAS OR LEUKEMIAS
    Publication number: 20180222985
    Abstract: The present invention relates to anti-CSF-1R induced lymphocytosis in lymphomas and leukemias and a combination therapy of antibodies which bind human CSF-1R with antibodies which bind human CD20.
    Type: Application
    Filed: June 23, 2016
    Publication date: August 9, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Maria Teresa Sabrina BERTILACCIO, Federico CALIGARIS-CAPPIO, Giovanni GALLETTI, Christian KLEIN, Carola RIES
  • 3-substituted 5-amino-6H-thiazolo[4,5-d]pyrimidine-2,7-dione compounds for the treatment and prophylaxis of virus infection
    Patent number: 10040815
    Abstract: The present invention relates to compounds of formula (I), wherein R1, R2 and R3 are as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: July 11, 2016
    Date of Patent: August 7, 2018
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Dongdong Chen, Song Feng, Lu Gao, Chao Li, Baoxia Wang, Lisha Wang, Hongying Yun, Xiufang Zheng
  • NOVEL SOLUBLE SORTASE A
    Publication number: 20180216091
    Abstract: Herein is reported a polypeptide comprising the amino acid sequence of SEQ ID NO: 38 as sole Listeria monocytogenes derived polypeptide and its use in conjugating polypeptides.
    Type: Application
    Filed: March 23, 2018
    Publication date: August 2, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Mara Boenitz-Dulat, Martin Schatte
  • NEW BICYCLIC COMPOUNDS AS DUAL ATX/CA INHIBITORS
    Publication number: 20180215765
    Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, Y, W, m, n, p and q are as defined herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: March 23, 2018
    Publication date: August 2, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Patrick Di Giorgio, Jerome Hert, Daniel Hunziker, Patrizio Mattei, Markus Rudolph, Petra Schmitz, Christoph Ullmer
  • BICYCLIC COMPOUNDS AS DUAL ATX/CA INHIBITORS
    Publication number: 20180208601
    Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R9, Y, W, m, n, p and q are as defined herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: March 23, 2018
    Publication date: July 26, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Jerome Hert, Daniel Hunziker, Patrizio Mattei, Markus Rudolph, Petra Schmitz, Christoph Ullmer
  • NEW BICYCLIC COMPOUNDS AS ATX INHIBITORS
    Publication number: 20180208602
    Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R9, Y, W, m, n, p and q are as defined herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: March 23, 2018
    Publication date: July 26, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Patrick Di Giorgio, Jerome Hert, Daniel Hunziker, Patrizio Mattei, Markus Rudolph, Petra Schmitz
  • ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF
    Publication number: 20180208662
    Abstract: The present invention relates to antibodies against human CSF-1R (anti-CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: December 21, 2017
    Publication date: July 26, 2018
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Nikolaos DIMOUDIS, Georg FERTIG, Alexander FIDLER, Klaus KALUZA, Marlene THOMAS, Carola RIES, Stefan SEEBER, Martin LANZENDOERFER
  • Antibodies against human CSF-1R and uses thereof
    Patent number: 10030073
    Abstract: The present invention relates to antibodies against human CSF-1R (CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: October 4, 2016
    Date of Patent: July 24, 2018
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Georg Fertig, Alexander Fidler, Klaus Kaluza, Marlene Thomas, Carola Ries, Stefan Seeber
  • Imidazole derivatives
    Patent number: 10029989
    Abstract: The present invention relates to compounds of formula I wherein R1? is CH3; R1 is methyl, ethyl, CF3, cyclopropyl, CH2OH or R1? and R1 may form together with the carbon atom to which they are attached a 1,1-dioxo-thiolan-3-yl ring; R2 is hydrogen, methyl, ethyl, isopropyl, tertbutyl, cyclopropyl, CH2OH or C(CH3)2OH; R3 is Cl, F, CF3, cyano, methyl or cyclopropyl; R4 is hydrogen, methyl or F; or to a pharmaceutically acceptable salt or acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof for use in the treatment of psychiatric disorders such as schizophrenia, bipolar disorder, obsessive-compulsive disorder or autism spectrum disorder.
    Type: Grant
    Filed: December 4, 2017
    Date of Patent: July 24, 2018
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Marius Hoener, Juergen Wichmann
  • Peptide macrocycles against acinetobacter baumannii
    Patent number: 10030047
    Abstract: The present invention provides compounds of formula (I) wherein X1 to X8 and R1 to R8 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula (I), pharmaceutical compositions comprising them and their use as medicaments for the treatment of diseases and infections caused by Acinetobacter baumannii.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: July 24, 2018
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Alexander Alanine, Julien Beignet, Konrad Bleicher, Bernhard Fasching, Hans Hilpert, Taishan Hu, Dwight MacDonald, Stephen Jackson, Sabine Kolczewski, Carsten Kroll, Adrian Schaeublin, Hong Shen, Theodor Stoll, Helmut Thomas, Amal Wahhab, Claudia Zampaloni
  • COMBINATION THERAPY OF TUMOR-TARGETED IL-2 VARIANT IMMUNOCYTOKINES AND ANTIBODIES AGAINST HUMAN PD-L1
    Publication number: 20180200338
    Abstract: The present invention relates to the combination therapy of specific tumor-targeted IL-2 variant immunocytokines with specific antibodies which bind human PD-L1.
    Type: Application
    Filed: December 21, 2017
    Publication date: July 19, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Pablo Umana, Christian Klein, Valeria G. Nicolini
  • SPECTROSCOPIC FINGER-PRINTING OF RAW MATERIALS
    Publication number: 20180202938
    Abstract: The invention provides a method for the selection of cultivation component batches to be used in the cultivation of a mammalian cell expressing a protein of interest wherein at least two different components are employed in the cultivation.
    Type: Application
    Filed: September 22, 2017
    Publication date: July 19, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Jose Cardoso-Menezes, Christian Hakemeyer, Gledson Emidio Jose, Ulrike Strauss, Silke Werz
  • BIOMARKERS FOR HBV TREATMENT RESPONSE
    Publication number: 20180201997
    Abstract: The present invention relates to methods that are useful for predicting the response of hepatitis B virus (HBV) infected patients to pharmacological treatment.
    Type: Application
    Filed: June 16, 2016
    Publication date: July 19, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Hua He, Cynthia Wat
  • PHENOXYMETHYL DERIVATIVES
    Publication number: 20180201588
    Abstract: The invention provides novel compounds having the general formula (I) wherein RA, RB, RC, RC1 and W are as defined herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: March 2, 2018
    Publication date: July 19, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Jerome Hert, Daniel Hunziker, Holger Kuehne, Thomas Luebbers, Rainer E. Martin, Patrizio Mattei, Werner Neidhart, Hans Richter, Markus Rudolph
  • TARGETED NOTCH PATHWAY INHIBITORS
    Publication number: 20180200262
    Abstract: The instant invention relates to novel conjugates of the compound of formula (I): S-L-A ??(I) or salts thereof, wherein A is a ?-secretase inhibitor, L is a linker and S is a peptidase-specific substrate, as well as processes for their manufacture, pharmaceutical compositions comprising them, and their use as medicaments.
    Type: Application
    Filed: December 11, 2017
    Publication date: July 19, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Johannes Aebi, Alexander Flohr, Juillerat-Jeanneret Lucienne, Golshayan Dela
  • Antibodies against human CSF-1R and uses thereof
    Patent number: 10023643
    Abstract: The present invention relates to antibodies against human CSF-1R (CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: December 12, 2012
    Date of Patent: July 17, 2018
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Georg Fertig, Alexander Fidler, Klaus Kaluza, Carola Ries, Stefan Seeber, Marlene Thomas
  • Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators
    Patent number: 10023589
    Abstract: Compounds of the formula I or II: wherein X, m, Ar, R1 and R2 are as defined herein. The subject compounds are useful for treatment of IRAK-mediated conditions.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: July 17, 2018
    Assignees: Hoffmann-La Roche Inc., Roche Palo Alto LLC
    Inventors: Nidhi Arora, Shaoqing Chen, Johannes Cornelius Hermann, Andreas Kuglstatter, Sharada Shenvi Labadie, Clara Jeou Jen Lin, Matthew C. Lucas, Amy Geraldine Moore, Eva Papp, Francisco Xavier Talamas, Jutta Wanner, Yansheng Zhai
  • Sulfinylphenyl or Sulfonimidoylphenyl Benzazepines
    Publication number: 20180194735
    Abstract: This invention relates to novel sulfinylphenyl or sulfonimidoylphenyl benzazepine compounds of the formula wherein X and R1 to R6 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are TLR agonists and may therefore be useful as medicaments for the treatment of diseases such as cancer, autoimmune diseases, inflammation, sepsis, allergy, asthma, graft rejection, graft-versus-host disease, immunodeficiencies, and infectious diseases.
    Type: Application
    Filed: March 8, 2018
    Publication date: July 12, 2018
    Applicant: Hoffmann La-Roche Inc.
    Inventors: Sabine Hoves, Lisha Wang, Hongying Yun, Weixing Zhang, Wei Zhu
  • COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY
    Publication number: 20180194781
    Abstract: The present invention provides compounds of formula (I) wherein A, X, Y, R1 and R2 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula (I), pharmaceutical compositions comprising them and their use as medicaments.
    Type: Application
    Filed: November 16, 2017
    Publication date: July 12, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Robert Jack Gillespie, Hasane Ratni, Jerome Charles Sarie
  • AFFINITY CHROMATOGRAPHY PURIFICATION WITH LOW CONDUCTIVITY WASH BUFFER
    Publication number: 20180186866
    Abstract: Herein is reported a method for producing a bispecific antibody comprising a first antigen-binding site that specifically binds to a first antigen and a second antigen-binding site that specifically binds to a second antigen comprising the following steps a) cultivating a cell comprising a nucleic acid encoding the bispecific antibody, b) recovering the bispecific antibody from the cell or the cultivation medium, c) contacting the bispecific antibody with an affinity chromatography material, d) washing the affinity chromatography material with a low conductivity aqueous solution, wherein the low conductivity aqueous solution has a conductivity value of about 0.5 mS/cm or less, e) recovering the bispecific antibody from the affinity chromatography material, f) performing a further chromatography step and thereby producing the bispecific antibody.
    Type: Application
    Filed: February 20, 2018
    Publication date: July 5, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Roberto FALKENSTEIN, Eva ROSENBERG, Agathe BIALAS, Steffen WILLMANN